ArticleClinical, cosmetic and investigational dermatology2015
Update on the management of rosacea.
Article in Clinical, cosmetic and investigational dermatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.
- Laser and light-based therapies in the management of rosacea: an updated systematic review.Lasers in medical science · 2021Pooled it
- Long-term inflammatory rosacea management with subantibiotic dose oral doxycycline 40 mg modified-release capsules once daily.Dermatologic therapy · 2022Trial
- Article
- Efficacy and Effectiveness of High Molecular Weight Non-Cross-Linked Hyaluronic Acid Plus Succinic Acid Mesotherapy in Rosacea as Adjunct Therapy.Journal of cosmetic dermatology · 2025Article
- Treatment of Metophyma with Isotretinoin.Acta dermato-venereologica · 2024Article
- Ultrasound-Guided Stellate Ganglion Block Combined with Pharmacological Treatment for Rosacea: A Report of Two Cases.Patient preference and adherence · 2024Article
- Rosacea Topical Treatment and Care: From Traditional to New Drug Delivery Systems.Molecular pharmaceutics · 2023Review
- Development of a Specific Variant of Patient Benefit Index (PBI) Assessing Patient Needs, Goals and Benefits in Rosacea Treatment.Patient preference and adherence · 2023Article
- Successful Treatment of Minocycline-Induced Facial Hyperpigmentation with a Combination of Chemical Peels and Intense Pulsed Light.Clinical, cosmetic and investigational dermatology · 2023Article
- Multitarget Approaches against Multiresistant Superbugs.ACS infectious diseases · 2020Review
- Management of severe rhinophyma with electrocautery dermabrasion - A case report.International journal of surgery case reports · 2020Article
- Botulin Toxin Use in Rosacea and Facial Flushing Treatment.Open access Macedonian journal of medical sciences · 2019Review
- Effect of recombinant bovine basic fibroblast growth factor gel on repair of rosacea skin lesions: A randomized, single-blind and vehicle-controlled study.Experimental and therapeutic medicine · 2019Article
- New trends in botulinum toxin use in dermatology.Dermatology practical & conceptual · 2018Article
- Rosacea: Molecular Mechanisms and Management of a Chronic Cutaneous Inflammatory Condition.International journal of molecular sciences · 2016Review
- Improving Treatment of Erythematotelangiectatic Rosacea with Laser and/or Topical Therapy Through Enhanced Discrimination of its Clinical Features.The Journal of clinical and aesthetic dermatology · 2016Review
- Combination of new multifunctional molecules for erythematotelangiectatic rosacea disorder.Clinical, cosmetic and investigational dermatology · 2015Article
- Consensus on the therapeutic management of rosacea - Brazilian Society of Dermatology.Anais brasileiros de dermatologiaArticle
- Anti-inflammatory and Immunomodulatory Effects of Antibiotics and Their Use in Dermatology.Indian journal of dermatologyReview
Corrections and comments
- Reprinted as
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Refining diagnostic criteria has identified key characteristics differentiating rosacea, a chronic skin disorder, from other common cutaneous inflammatory conditions. The current classification system developed by the National Rosacea Society Expert Committee consists of erythematotelangiectatic, papulopustular, phymatous, and ocular subtypes. Each subtype stands as a unique entity among a spectrum, with characteristic symptoms and physical findings, along with an intricate pathophysiology. The main treatment modalities for rosacea include topical, systemic, laser, and light therapies. Topical brimonidine tartrate gel and calcineurin inhibitors are at the forefront of topical therapies, alone or in combination with traditional therapies such as topical metronidazole or azelaic acid and oral tetracyclines or isotretinoin. Vascular laser and intense pulsed light therapies are beneficial for the erythema and telangiectasia, as well as the symptoms (itching, burning, pain, stinging, swelling) of rosacea. Injectable botulinum toxin, topical ivermectin, and microsecond long-pulsed neodymium-yttrium aluminum garnet laser are emerging therapies that may prove to be extremely beneficial in the future. Once a debilitating disorder, rosacea has become a well known and manageable entity in the setting of numerous emerging therapeutic options. Herein, we describe the treatments currently available and give our opinions regarding emerging and combination therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.